José Antonio de la Puente has been the CEO of Alcaliber S.A.U. since 2004. Alcaliber is a leading independent supplier of active pharmaceutical ingredients for the international pharmaceutical industry. He is also the CEO of Linneo Health since October 2018, a Spanish Company founded for the activities of cultivation, production, manufacturing, import, export, distribution and trade of cannabis and cannabis products for medical and scientific purposes, as well as research linked to the development of these activities.
Javier Fernández-Ruiz is Professor in the Department of Biochemistry and Molecular Biology, Faculty of Medicine at the Complutense University of Madrid. He is currently the Principal Investigator of the “Cannabinoids and Neurological Disorders” research group at the Complutense University. The main activity of this group is the study of the therapeutic potential of cannabinoids in several neurological diseases, mainly neurodegenerative, activity addressed to the design, synthesis and biological characterization of novel cannabinoids with neuroprotective profile, and to test their therapeutic efficacy at preclinical and clinical levels. Professor Fernandez is also a member of the Editorial Board in the British Journal of Pharmacology.
Carola Pérez has a degree in Audiovisual Communication, a field to which she has dedicated most of her professional life. She currently chairs the Spanish Medicinal Cannabis Observatory and is the founder of the association of therapeutic users dosemociones, where she advises, supports all those patients who use cannabis for medicinal purposes and works for the regulation of therapeutic cannabis.
Sarah Meryll Buet started her career in capital markets between London & Paris, where she has developed a passion for Sciences & Innovation. After having helped to develop Alkion BioPharma, Sarah founded Alkion BioInnovations (Alkinnov), a biotech company developing innovative GMO-free plant-based active ingredients using sustainable patented biotechnologies.
Bruno Maia is a Portuguese MD, specialist in Neurology and Critical Care Medicine. He works in the acute care of stroke patients and is responsible for the Neurovascular Ultrasonographic Laboratory at Centro Hospitalar de Lisboa Central (terciary hospital located in Lisbon).
Viola Brugnatelli is the scientific director of Cannabiscienza, an e-learning academy for Italian health care professionals on Medical Cannabis and the Endocannabinoid System. Dr Brugnatelli is a lecturer on Medical Cannabis at the University of Padua (Italy) as well as a researcher at the Department of Neuroscience within the same institute. Since 2012 she is an active member of IACM and ICRS, and was recently nominated IACM Italian Ambassador. Dr Brugnatelli advocates for patient-inspired clinical research and collaborates with non-for-profit organisations. In 2018 Brugnatelli co-founded a non-for-profit which lobbies for women equality in the European cannabis sphere.
Dr Tina Horsted is a doctor who specialises in prescribing medicinal cannabis. Two years ago, she started the public pain clinic Min Smerte. Dr Horsted and her team treat more than 1,200 patients in their clinic who suffer from chronic pain, MS, RA and cancer.
Stephen Murphy is Co-Founder of NOBL Group, a global leader in cannabis data and media. Stephen is also Co-Founder of Prohibition Partners, the leading source of intelligence and insights into the European cannabis industry. He is also Co-Founder of Cannabis Europa.
Cristina Romero de Alba is a Partner at LOYRA Abogados y Asesores since April 2011. She leads the international practice area of Loyra. Cristina regularly advises operators and investors in licensing, M&A and general regulatory and compliance procedures in regulated industries including cannabis for medicinal, cosmetics and food use.
Dr. Moreno-Sanz has authored 25+ scientific articles and 3 patents describing the role of the endocannabinoid system on pain perception. He gained broad international experience with long-term fellowships in the Netherlands, Italy and the US, where he has developed most of his career at the University of California, Irvine, working with Prof. Daniele Piomelli, where he discovered a new class of cannabinoid analgesics devoid of unwanted psychoactivity. He participated in the elaboration of the 2017 report “The Health Effects of Cannabis and Cannabinoids” by the National Academies of Sciences. He then relocated to Spain and founded Abagune Research, a privately-owned company that provides scientific advise, research solutions and product development services to regulators, disseminators and operators within the international cannabis industry.
Dr. Patrizia Carrieri is a researcher at the French National Institute of Health and Medical research (INSERM). She has a background in methods for epidemiologic research. Her research interests focus on access to care and prevention of HIV and HCV in people who use drugs (PWUD). Dr. Carrieri is currently the scientific director of a national non-inferiority randomized trial evaluating long-term outcomes of methadone induction in primary care (ANRS Methaville).
Dr. Verónica Codesido is the Manager of Breeding and Cultivation Department of Phytoplant Research S.L, the first authorized Spanish company to work with Cannabis sativa for research purposes. She is Doctor in Biology and have many years of experience as a breeder of many kinds of species. She developed her postdoc on in vitro culture and molecular biology of forest species and, nowadays, she is using all the learnt techniques to improve and accelerate the Cannabis breeding program of the company.